Clinical Without Histopathological Manifestations of Inflammation in a Patient With Primary Intraorbital Optic Nerve Sheath Meningioma

Secretory meningiomas of the orbit

Meningiomas are histologically heterogeneous tumors with at least 15 different subtypes. They can be subdivided into well-differentiated, atypical, and anaplastic or malignant categories. The secretory meningioma is a well-differentiated variant, is relatively rare. Orbital involvement of secretory meningiomas is rarity. We report two cases of secretory meningiomas of orbit and review of current literature.

Primary optic nerve tumours

PURPOSE OF REVIEW

Advances have been made in the treatment of primary optic nerve tumours. With a focus on the last few years' publications, recommendations for clinical management are being developed.

RECENT FINDINGS

In low-grade optic nerve glioma, two divergent developments are observed: an increasing reluctance in treating such tumours because of reports about treatment toxicity (secondary tumours, moyamoya syndrome) and a steady and marked improvement both in radiotherapy and chemotherapy. Many reports on beneficial effects of radiotherapy on optic nerve meningioma have been published. Radiotherapy does not only preserve but in many cases even improves or restores visual function and has, therefore, become the therapy of choice in this tumour.

SUMMARY

Establishing a treatment plan in cases of optic nerve glioma is difficult and must be made on an individual basis. Although both chemotherapy and radiotherapy can stabilize and sometimes improve vision in progressive tumours, chemotherapy is the preferred modality in children younger than 9 years and in patients with neurofibromatosis 1. In functionally progressive optic nerve meningioma with useful visual function, multifractioned stereotactic conformal radiotherapy is the treatment of choice.